Dataset Information

Targeting branched-chain amino acids alleviates pulmonary fibrosis [scRNA-seq]

ABSTRACT: We previously confirmed that BCAT2 was reduced in TGF-β1-treated mouse and human lung fibroblasts. Knockdown of BCAT2 significantly promoted COL1A1 expression in response to TGF-β1 treatment. However, the roles of BCAT2 on other cell types, changes in cellular states, and cellular interactions are currently unknown. Here, we used single-cell RNA sequencing to analysis healthy mouse lungs (WT_PBS), mouse lungs with bleomycin-induced fibrosis (WT_BLM), and heterozygous BCAT2+/− (BCAT2 Het) mouse lungs treated with BLM (Het_BLM). Notably, we observed a reduced number of epithelial cells in the BCAT2 Het mice (Figure 3M and S3L). In contrast, the fibroblast and macrophage populations were significantly increased in the BCAT2 Het mice compared to WT mice after bleomycin-induced lung injury.

ORGANISM(S): Mus musculus

PROVIDER: GSE295427 | GEO | 2026/03/17

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:AbstractBackground: Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive pulmonary disease, and effective therapies to reverse the natural course of IPF are lacking. A growing number of studies have shown that the use of human umbilical cord-derived mesenchymal stem cells (HUC-MSCs) is a promising therapeutic strategy. However, the mechanism by which HUC-MSCs alleviate IPF and how HUC-MSCs affect the lung microbiota are still unclear and need further exploration.Methods: Bleomycin (BLM) injection was utilized to establish a mouse model of IPF, followed by the application of 16S rDNA sequencing and LC‒MS/MS metabolomics to explore the underlying mechanism of HUC‒MSC treatment for IPF. Thirty mice were allocated into three groups, namely, the control, BLM, and BLM+HUC-MSC groups, and their lung morphology; the levels of α-SMA, FN1 and COL1A1; and the levels of the inflammatory cytokines TNF-α, IL-1β, IL-6, and TGF-β1 were subsequently evaluated. Bronchoalveolar lavage fluid (BALF) samples from six mice in each of the control, BLM, and BLM+HUC-MSC groups were collected randomly for 16S rDNA sequencing to analyze the lung microbiota and untargeted metabolomics.Results: Compared with IPF model mice, HUC-MSCs restored alveolar morphology and reduced the expression of α-SMA, FN1 and COL1A1 and the inflammatory cytokines TNF-α, IL-1β, IL-6, and TGF-β1, confirming the anti-inflammatory properties of HUC-MSCs in IPF treatment. The findings from the 16S rDNA sequencing indicated that HUC-MSC treatment effectively decreased α diversity indices, such as ACE and Shannon indices, as well as β diversity, leading to a decrease in microbiota abundance. The findings from the metabolomics analysis revealed that the metabolites exhibiting notable differences were composed primarily of organic acids and their derivatives, lipids and lipid-like molecules, phenylpropanoids and polyketides, and organic nitrogen compounds, indicating the potential of HUC-MSCs to exert antifibrotic effects via these metabolic pathways.Conclusions: Overall, our study preliminarily confirmed that IPF in mice was closely related to microbial and metabolic dysbiosis. HUC-MSC treatment modulated dysregulated metabolic pathways in mice with IPF, restoring abnormal microbiota function to that of the control group. This study provides new insights into the potential mechanisms and treatments of IPF.

Dataset Information

Targeting branched-chain amino acids alleviates pulmonary fibrosis [scRNA-seq]

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets